Universiti Sains Malaysia, School of Medical Sciences, Department of Emergency Medicine, Kubang Kerian, Malaysia.
Med J Malaysia. 2023 Mar;78(2):171-176.
Risk stratification tools that integrate clinical, ECG findings and cardiac biomarkers have been used to facilitate the management of chest pain patients in the emergency department (ED). We studied the feasibility of history, age, electrocardiogram and risk factors (HEAR) score as a risk stratification tool for chest pain patients presented to ED Hospital Universiti Sains Malaysia (HUSM) in comparison to modified HEART score (MHS) based on major adverse cardiac events (MACE) within 6 weeks' time.
We analysed retrospective data of chest pain patients presenting to ED HUSM from 1st June 2020 till 31st January 2021 based on the patient's history, ECG findings, risk factors, age and troponin level. The patients were stratified as low risk (MHS and HEAR score of 0-3), intermediate risk (MHS and HEAR score of 4-6), and high risk (MHS of 7-10 and HEAR score of 7-8). The association of the MHS and HEAR score with MACE at 6 weeks' time was evaluated using simple logistic regression.
This study included 147 patients in the MHS analysis and 71 patients in HEAR score analysis. The incident rate of MACE in low, intermediate and high risk was 0%,16.3%, and 34.7%, in the MHS group, and 0%, 3.22%, and 6.66% in HEAR score group. The mean difference between MACE and non-MACE in MHS and HEAR score groups was -2.29 (CI: -3.13,1.44, p<0.001) and -2.51(CI: -5.23, 0.21, p=0.070), respectively. There was no significant association between the incidence rate of MACE with modified HEART score (MHS) and HEAR score groups (p>0.95).
HEAR score is not feasible to be used as a risk stratification tool for chest pain patients presenting to ED HUSM in comparison to MHS. Further studies are required to validate the results.
已使用整合临床、心电图发现和心脏生物标志物的风险分层工具来帮助急诊科(ED)胸痛患者的管理。我们研究了历史、年龄、心电图和危险因素(HEAR)评分作为风险分层工具的可行性,将其与基于 6 周内主要不良心脏事件(MACE)的改良 HEART 评分(MHS)相比,在马来西亚理科大学医院 ED 就诊的胸痛患者。
我们分析了 2020 年 6 月 1 日至 2021 年 1 月 31 日在 ED HUSM 就诊的胸痛患者的回顾性数据,依据患者的病史、心电图发现、危险因素、年龄和肌钙蛋白水平进行分层。患者被分为低危(MHS 和 HEAR 评分 0-3)、中危(MHS 和 HEAR 评分 4-6)和高危(MHS 7-10 和 HEAR 评分 7-8)。使用简单逻辑回归评估 MHS 和 HEAR 评分与 6 周时 MACE 的关系。
本研究包括 MHS 分析的 147 例患者和 HEAR 评分分析的 71 例患者。低危、中危和高危患者的 MACE 发生率分别为 MHS 组 0%、16.3%和 34.7%,HEAR 评分组 0%、3.22%和 6.66%。MHS 和 HEAR 评分组 MACE 和非 MACE 之间的平均差异分别为-2.29(CI:-3.13,1.44,p<0.001)和-2.51(CI:-5.23,0.21,p=0.070)。MACE 发生率与改良 HEART 评分(MHS)和 HEAR 评分组之间无显著关联(p>0.95)。
与 MHS 相比,HEAR 评分不适用于 ED HUSM 就诊的胸痛患者的风险分层工具。需要进一步的研究来验证结果。